Nephrogenic Systemic Fibrosis and Management of High-risk Patients

Academic Radiology

Volumn 16, Issue 7, 2009, Pages 897-905

  Altun, Ersan ^a   Semelka, Richard C ^a   Cakit, Ceylan ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

gadolinium; MRI; Nephrogenic systemic fibrosis; renal insufficiency; stability

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IODINATED CONTRAST MEDIUM;

COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; DIAGNOSTIC ACCURACY; DIALYSIS; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; THERMOSTABILITY;

CONTRAST MEDIA; GADOLINIUM; INCIDENCE; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RISK ASSESSMENT; RISK FACTORS;

EID: 67349189524     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2009.01.001     Document Type: Review

References (66)

1. Cowper S.E., Robin H.S., Steinberg S.M., et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 (2000) 1000-1001
2. Cowper S.E., Su L.D., Bhawan J., et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 (2001) 383-393
3. Daram S.R., Cortese C.M., and Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 46 (2005) 754-759
4. Broome D.R., Girguis M.S., Baron P.W., et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188 (2007) 586-592
5. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis. Nephrol Dial Transplant 21 (2006) 1104-1108
6. Sadowski E.A., Bennett L.K., Chan R.M., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148-157
7. Collidge T.A., Thomson P.C., Mark P.B., et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245 (2007) 168-175
8. Shabana W.M., Cohan R.H., Ellis J.H., et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 190 (2008) 736-741
9. Lauenstein T.C., Salman K., Morreira R., et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 26 (2007) 1190-1197
10. Public health advisory: gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. U.S. Food and Drug Administration. www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Published June 8, 2006. Updated May 23, 2007. Accessed July 12, 2008.
11. Thomsen H.S. Nephrogenic systemic fibrosis. Imaging Decisions MRI 11 (2008) 13-18
12. Kuo P.H., Kanal E., Abu-Alfa A.K., et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242 (2007) 647-649
13. Thomsen H.S. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis. Acta Radiologica 48 (2007) 593-596
14. Galan E., Cowper S.E., and Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18 (2006) 614-617
15. Thomsen H.S. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 17 (2007) 2692-2696
16. Rofsky N.M., Sherry D.A., and Lenkinski L.E. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247 (2008) 608-612
17. Wertman R., Altun E., Martin D.R., et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents by four American universities. Radiology 248 (2008) 799-806
18. Bucala R. Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol 5 (2008) 36-39
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002) S46-S75
20. Rydahl C., Thomsen H.S., and Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 43 (2008) 141-144
21. Joffe P., Thomsen H.S., and Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5 (1998) 491-502
22. Kanal E., Barkovich J.A., Bell C., et al. ACR Guidance document for safe MR practices: 2007. AJR Am J Roentgenol 188 (2007) 1-27
23. American College of Radiology. Manual on contrast media version 6, 2008. Nephrogenic systemic fibrosis (2008) 53-57
24. Marckmann P. Nephrogenic systemic fibrosis: epidemiology update. Curr Opin Nephrol Hypertens 17 (2008) 315-319
25. Prince M.R., Zhang H., Morris M., et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248 (2008) 807-816
26. Lin S.-P., and Brown J.J. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 25 (2007) 884-899
27. Idee J.-M., Port M., Raynal I., et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20 (2006) 563-576
28. Gibby W.A., Gibby K.A., and Gibby W.A. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39 (2004) 138-142
29. High W.A., Ayers R.A., Chandler J., et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 (2007) 21-26
30. High W.A., Ayers R.A., and Cowper S.E. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 (2007) 710-712
31. Marckmann P., Skov L., Rossen K., et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22 (2007) 3174-3178
32. Morcos S.K. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 66 (2008) 175-179
33. Thomsen H.S. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16 (2006) 2619-2621
34. Colletti P.M. Nephrogenic systemic fibrosis and gadolinium: a perfect storm. AJR 191 (2008) 1-4
35. Grobner T., and Prischl F.C. Patient characteristics and risk factors for nephrogenic systemic fibrosis for gadolinium exposure. Semin Dial 21 (2008) 135-139
36. Thomsen H.S. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16 (2006) 2619-2621
37. Parsons A.C., Yosipovitch G., Sheehan D.J., et al. Transglutaminase: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol 29 (2007) 433-436
38. Kucher C., Xu X., Pasha T., et al. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 32 (2005) 484-490
39. Nainani N., and Panesar M. Nephrogenic systemic fibrosis. Am J Nephrol 29 (2008) 1-9
40. Mathur K., Morris S., Deighan C., et al. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher 23 (2008) 144-150
41. Kay J., and High W.A. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 58 (2008) 2543-2548
42. Evenepoel P., Zeegers M., Segaert S., et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 19 (2004) 469-473
43. Prokop M., Schneider G., Vanzulli A., et al. Contrast-enhanced MR angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentate dimeglumine. Radiology 234 (2005) 399-408
44. Schneider G., Maas R., Schultze Kool L., et al. Low-dose gadobenate dimeglumine versus standard dose gadopentate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 38 (2003) 85-94
45. Volk M., Strotzer M., Lenhart M., et al. Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentate dimeglumine with different doses. Radiology 220 (2001) 484-488
46. Huppertz A., Balzer T., Blakeborough A., et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid - enhanced MR images with intraoperative findings. Radiology 230 (2004) 266-275
47. Coresh J., Astor B.C., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
48. Shellock F.G., and Spinazzi A. MRI safety update 2008: Part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR 191 (2008) 1-11
49. Saab G., and Abu-Alfa A. Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?. AJR 189 (2007) W169
50. Broome D.R., Cottrell A.C., and Kanal E. Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?". AJR 189 (2007) W234-W235
51. Mehran R., and Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int 69 (2006) S11-S15
52. Gleeson T.G., and Bulugahapatiya S. Contrast-induced nephropathy. AJR 183 (2004) 1673-1689
53. Murphy S.W., Barrett B.J., and Parfrey P.S. Contrast nephropathy. J Am Soc Nephrol 11 (2000) 177-182
54. Solomon R., Biguori C., and Bettmann M. Selection of contrast media. Kidney Int 69 (2006) S39-S45
55. Tombach B., Bremer C., Reimer P., et al. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol 178 (2002) 105-109
56. Ergun I., Keven K., Uruc I., et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 21 (2006) 697-700
57. McCullough P., Adam A., Becker C.R., et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 98 (2006) 5K-13K
58. Perrson P.B., and Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int 69 (2006) S8-S10
59. Persson P.B., Hansell P., and Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 68 (2005) 14-22
60. Katzberg R.W., and Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int 69 (2006) S3-S7
61. Katzberg R.W., and Barrett B.J. Risk of iodinated contrast material-induced nephropathy with intravenous administration. Radiology 243 (2007) 622-628
62. Thomsen H.S., Morcos S.K., Erley C., et al. The ACTIVE trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 43 (2008) 170-178
63. Levy E.M., Viscoli C.M., and Horwitz R.I. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275 (1996) 1489-1494
64. Cheruvu B., Henning K., Mulligan J., et al. Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations. J Comput Assist Tomogr 31 (2007) 493-498
65. Weinreb J.C. Which study when? Is gadolinium-enhanced MR imaging safer than iodine-enhanced CT?. Radiology 249 (2008) 3-8
66. Halvorsen R.A. Which study when? Iodinated contrast-enhanced CT versus gadolinium-enhanced MR imaging. Radiology 249 (2008) 9-15